Abstract
Rheumatic diseases in women of childbearing years may necessitate drug treatment during a pregnancy, to control maternal disease activity and to ensure a successful pregnancy outcome. This survey is based on a consensus workshop of international experts discussing effects of anti-inflammatory, immunosuppressive and biological drugs during pregnancy and lactation. In addition, effects of these drugs on male and female fertility and possible long-term effects on infants exposed to drugs antenatally are discussed where data were available. Recommendations for drug treatment during pregnancy and lactation are given.
Highlights
The pregnancy categories of the United States Food and Drug Administration (FDA) in their present form are often not helpful for the clinician treating patients with active chronic disease during pregnancy and lactation
There was no significant difference in perinatal mortality (RR 0.92; 95% confidence interval (CI) 0.81 to 1.05) and in the rate of small-for-gestational-age infants (12 studies; RR 0.96; 95% CI 0.87 to 1.07) among offspring of mothers treated with aspirin and those of mothers treated with a placebo [5]
Stress doses of hydrocortisone at delivery are recommended in patients on long-term therapy
Summary
The pregnancy categories of the United States Food and Drug Administration (FDA) in their present form are often not helpful for the clinician treating patients with active chronic disease during pregnancy and lactation. They combine risk assessment and benefit, and are for most products based on animal data. Even the recommendations given by the producer of a given drug can vary in different countries This situation is unsatisfying for both the patient and the treating physician. For this reason an international workshop of experts with experience in drug therapy of pregnant and lactating women was arranged. The aim was to reach a consensus on antiinflammatory and immunosuppressive drugs during pregnancy and lactation with a focus on patients with rheumatic disease
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
